National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Ruxolitinib (Jakavi®) for Polycythaemia Vera. HTA ID: 20008

Ruxolitinib (Jakavi®) is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.

Rapid Review

Commenced Completed Outcome
15/04/2015 28/05/2015 Full Pharmacoeconomic Evaluation Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
13/04/2016  16/08/2016 Reimbursement Not Recommended


Resubmission of HTA

NCPE Assessment Process Complete
Resubmission of HTA commissioned by HSE/ 04/03/2020
Pre-submission consultation with Applicant 09/03/2020
Full HTA submission received from applicant 16/09/2020
Preliminary review sent to applicant 01/04/2021
NCPE assessment re-commenced 04/05/2021
Follow-up preliminary review sent to Applicant 19/05/2021
NCPE assessment re-commenced 26/05/2021
Factual accuracy sent to Applicant 28/06/2021
NCPE assessment re-commenced 09/07/2021
NCPE assessment completed 21/07/2021
NCPE assessment outcome

The NCPE recommends that ruxolitinib (Jakavi®) not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.